Summary
This website provides comprehensive information about a biologic medication indicated for the treatment of several eosinophil-driven diseases, including severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. It offers resources for healthcare professionals, including prescribing information, patient profiles, and access to expert discussions on the medication's efficacy and safety. The site emphasizes the importance of understanding the role of eosinophils in these conditions and provides guidance on patient management and treatment options.
Based on content on nucalahcp.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
8.4 years — Since Aug 2016
Web Hosting
Platform
E-Mail Provider
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Pharmaceuticals and Biologics
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
GlobalSign
TXT Record
TXT Record
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|